Click Here for 5% Off Your First Aladdin Purchase!

Satralizumab (anti-IL-6Ra) - Primary antibody, specific to IL6R, Human IgG2, Antibody of Interleukin-6 receptor

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Human
  • Isotype: Human IgG2
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175651
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175651-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
Ab175651-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$249.90
Ab175651-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$619.90
Ab175651-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$989.90

Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameSatralizumab (anti-IL-6Ra) - Primary antibody, specific to IL6R, Human IgG2
SynonymsEnspryng,RG-6168;RG6168;SA-237;SA237;sapelizumab (deprecated INN);satralizumab-mwge
Specifications & PurityCarrier Free, Recombinant, Low Endotoxin, Azide Free, Validated, ExactAb™, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityIL6R
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeANTAGONIST
Mechanism of actionAntibody of Interleukin-6 receptor
Product Description

Satralizumab (anti-IL-6RA), a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab (anti-IL-6RA) prevents dTAA formation and progression in rattus norvegicus. Satralizumab (anti-IL-6RA) can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg
Protein Function
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.
Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.

Product Properties

IsotypeHuman IgG2
Light Chain Typekappa
Purification MethodProtein A purified
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1535963-91-7

Associated Targets

IL6R Tclin Interleukin-6 receptor subunit alpha 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

IL6ST Tclin Interleukin-6 receptor subunit beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Heo YA.  (2020)  Satralizumab: First Approval..  Drugs,  80  (14): (1477-1482).  [PMID:32797372]

Solution Calculators